Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer

Molecular Endocrinology

Volumn 28, Issue 10, 2014, Pages 1629-1639

  Xie, Yingqiu ^a   Lu, Wenfu ^a   Liu, Shenji ^a   Yang, Qing ^a   Carver, Brett S ^b   Li, Estelle ^c   Wang, Yuzhuo ^c   Fazli, Ladan ^c   Gleave, Martin ^c   Chen, Zhenbang ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; BETA CATENIN; NUCLEAR MESENCHYMAL EPITHELIAL TRANSITION FACTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR; MET PROTEIN, HUMAN; SOX9 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RECURRENCE; CANCER TISSUE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL MEMBRANE; CELL NUCLEUS; CELL PROLIFERATION; CELL RENEWAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFANT; MALE; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PROSTATE CANCER CELL LINE; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; ANIMAL; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; PROSTATE; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR CELL LINE;

ANIMALS; BETA CATENIN; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; PROSTATE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; SOX9 TRANSCRIPTION FACTOR; TISSUE ARRAY ANALYSIS;

EID: 84907678055     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1078     Document Type: Article

References (49)

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4):232–240.
2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520.
3. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell. 2012;22(3):373–388.
4. Linn DE, Yang X, Sun F, et al. A role for OCT4 in tumor initiation of drug-resistant prostate cancer cells. Genes Cancer. 2010;1(9): 908–916.
5. Mulholland DJ, Kobayashi N, Ruscetti M, et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012;72(7):1878–1889.
6. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575–586.
7. Linn DE, Yang X, Xie Y, et al. Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-dependent recruitment of distinct ubiquitin E3 ligases. J Biol Chem. 2012;287(27): 22959–22968.
8. Guo Z, Dai B, Jiang T, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell. 2006;10(4): 309–319.
9. Lu W, Xie Y, Ma Y, Matusik RJ, Chen Z. ARF represses androgen receptor transactivation in prostate cancer. Mol Endocrinol. 2013; 27(4):635–648.
10. Cai C, He HH, Chen S, et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011;20(4):457–471.
11. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12(2):89–103.
12. Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res. 2007;67(3):967–975.
13. Yoshioka T, Otero J, Chen Y, et al. b4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest. 2013; 123(2):682–699.
14. Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500–504.
15. Pozner-Moulis S, Pappas DJ, Rimm DL. Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density. Cancer Res. 2006;66(16):7976–7982.
16. Gomes DA, Rodrigues MA, Leite MF, et al. c-Met must translocate to the nucleus to initiate calcium signals. J Biol Chem. 2008;283(7): 4344–4351.
17. Nath D, Williamson NJ, Jarvis R, Murphy G. Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J Cell Sci. 2001;114(pt 6):1213–1220.
18. Athauda G, Giubellino A, Coleman JA, et al. c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res. 2006;12(14 pt 1):4154–4162.
19. Guo W, Keckesova Z, Donaher JL, et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell. 2012;148(5): 1015–1028.
20. Seymour PA, Freude KK, Tran MN, et al. SOX9 is required for maintenance of the pancreatic progenitor cell pool. Proc Natl Acad Sci USA. 2007;104(6):1865–1870.
21. Cai C, Wang H, He HH, et al. ERG induces androgen receptormediated regulation of SOX9 in prostate cancer. J Clin Invest. 2013;123(3):1109–1122.
22. Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan X. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res. 2007; 67(2):528–536.
23. Chesire DR, Isaacs WB. b-Catenin signaling in prostate cancer: an early perspective. Endocr Relat Cancer. 2003;10(4):537–560.
24. Sanges D, Romo N, Simonte G, et al. Wnt/b-catenin signaling triggers neuron reprogramming and regeneration in the mouse retina. Cell Rep. 2013;4(2):271–286.
25. Thomsen MK, Ambroisine L, Wynn S, et al. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res. 2010;70(3):979–987.
26. Mulholland DJ, Tran LM, Li Y, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 2011;19(6):792–804.
27. Lunardi A, Ala U, Epping MT, et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2013;45(7):747–755.
28. Xie Y, Burcu M, Linn DE, Qiu Y, Baer MR. Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression. Mol Pharmacol. 2010;78(2):310–318.
29. Xie Y, Liu S, Lu W, et al. Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis [published online May 21, 2014]. Mol Oncol. doi: 10.1016/j.molonc.2014.05.006.
30. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005;436(7051):725–730.
31. Choudhary C, Olsen JV, Brandts C, et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell. 2009;36(2):326–339.
32. Gonsalves FC, Klein K, Carson BB, et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/ wingless signaling pathway. Proc Natl Acad Sci USA. 2011; 108(15):5954–5963.
33. Chen Z, Carracedo A, Lin HK, et al. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci Signal. 2009;2(84): ra44.
34. Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol. 2001;3(9):802–808.
35. Wang SC, Nakajima Y, Yu YL, et al. Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol. 2006;8(12):1359–1368.
36. Fan S, Ma YX, Gao M, et al. The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair. Mol Cell Biol. 2001;21(15): 4968–4984.
37. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene. 2009; 28(43):3801–3813.
38. Wang YN, Hung MC. Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family. Cell Biosci. 2012;2(1):13.
39. Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res. 2006;12(1):123–130.
40. Ni CY, Murphy MP, Golde TE, Carpenter G. Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science. 2001;294(5549):2179–2181.
41. Qi J, Tripathi M, Mishra R, et al. The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell. 2013; 23(3):332–346.
42. Jeter CR, Liu B, Liu X, et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene. 2011;30(36):3833–3845.
43. Li Y, Li A, Glas M, et al. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci USA. 2011;108(24):9951–9956.
44. van Leenders GJ, Sookhlall R, Teubel WJ, et al. Activation of c- MET induces a stem-like phenotype in human prostate cancer. PLoS One. 2011;6(11):e26753.
45. Hynes PG, Kelly K. Prostate cancer stem cells: the case for model systems. J Carcinog. 2012;11:6.
46. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670): 554.
47. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358–362.
48. Huang WC, Chen YJ, Li LY, et al. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. J Biol Chem. 2011;286(23):20558–20568.
49. Xie Y, Xu K, Dai B, et al. The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene. 2006;25(1):70–78.